Biotech Values

[jbog]

Momenta Pharmaceuticals Announces EMINENCE Trial Results to be Presented At the 21st Annual Transcatheter Cardiovascular Therapeutics (TCT) Meeting
Press Release
Source: Momenta Pharmaceuticals
On Wednesday September 9, 2009, 8:00 am EDT


CAMBRIDGE, Mass., Sept. 9, 2009 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA - News), a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that clinical trial results from the Phase 2 EMINENCE trial of its rationally engineered anticoagulant, M118, will be presented at the 21st Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. The TCT conference is the world's largest educational meeting specializing in interventional vascular medicine, with approximately 12,000 people expected to attend.



The meeting will be held September 21-25, 2009 in San Francisco, CA. Sunil V. Rao, M.D. of Duke University Medical Center, co-principal investigator, will present "M118: A Novel Low Molecular Weight Heparin: First Report of the EMINENCE Phase 2 Trial Results" in the session entitled: Antithrombin Alternatives: Low Molecular Weight Heparins, Direct Anti-Thrombins, Xa Inhibitors and Emerging Agents: Session III: Emerging Alternatives for Anticoagulation and ACS. The presentation is scheduled for Thursday, September 24th at 11:23 a.m. Pacific Time and will be held in Room 135 of the Moscone Convention Center.